Study of KB803 eye drops for eye scrapes in DEB
Part of Brain & nervous system, Eyes & vision, Genetic & congenital, Injuries & trauma, Skin clinical trials.
This study tests an experimental eye drop (KB803) to see if it can reduce painful scrapes on the surface of the eye in people with dystrophic epidermolysis bullosa. You would be randomly assigned to receive either the study drops or a placebo (an inactive drop) for several months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of dystrophic epidermolysis bullosa (DEB) with a specific gene change.
- You must be at least 6 months old.
- You need to have a minimum number of painful eye surface scrapes (corneal abrasions) each month as defined by the study.
- You cannot be pregnant, nursing, or unwilling to use birth control during the trial.
- You cannot have started any new eye treatments or changed your eye care routine in the weeks before the study (except for artificial tears or preservative-free antibiotic drops).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests stem cell–derived “extra-cellular vesicles” (small natural cell packages) to help heal painful skin wounds in people with dystrophic epidermolysis bullosa (DEB). If you have suitable, untreated wounds and meet the safety requirements, you may be able to join and help researchers learn whether this treatment is beneficial.
This trial tests a gel called TCP-25 on wounds caused by a specific type of epidermolysis bullosa (DEB or JEB). It aims to see if the gel can help heal wounds and improve comfort.
This trial tests a new skin graft made with your own cells that have been genetically modified to produce a missing protein (collagen 7). It's for people with RDEB, a severe blistering condition, and aims to see if the graft can heal wounds safely.
This trial tests if a drug called Ev.FV can help heal wounds in people with dystrophic epidermolysis bullosa (DEB), a condition that causes fragile, blistering skin. It is for people with open wounds on their arms, legs, or trunk that are a specific size.
This trial tests a drug called efgartigimod (VYVGART) to see if it can lower harmful antibodies in people with certain blistering skin diseases—dystrophic epidermolysis bullosa (DEB) and epidermolysis bullosa acquisita (EBA). If you have these antibodies, this treatment might help reduce blistering.
This trial tests whether KB801 can help heal persistent corneal defects better than a placebo. It is for people with neurotrophic keratitis (a condition where the cornea loses sensation) that has not improved with standard care.
Hear when a new Dystrophic Epidermolysis Bullosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.